Accelerated approval programs are regulatory mechanisms designed to expedite the approval process for new drugs that address unmet medical needs, particularly in the treatment of serious or life-threatening conditions like cancer. These programs allow for earlier approval based on surrogate endpoints rather than traditional clinical outcomes, which can significantly shorten the time required to bring potentially life-saving treatments to patients.
